| Literature DB >> 34295957 |
Michael Fialkow1, Neko Castleberry2, Jason D Wright3, Jay Schulkin1, Vrunda B Desai4.
Abstract
PURPOSE: Eighty percent of the approximately 500,000 hysterectomies performed annually in the US are for benign indications. There is lack of consensus regarding concurrent removal of fallopian tubes and/or ovaries. Ovarian cancer risk reduction is the principal benefit but the adverse consequences of ovarian removal can include vasomotor disturbance, vaginal dryness, cardiovascular disease, osteoporosis, and cognitive decline. Emerging evidence on the role of fallopian tubes in ovarian carcinogenesis and the consequences of oophorectomy have led the American College of Obstetricians-Gynecologists (ACOG) to recommend bilateral salpingectomy with ovarian conservation during benign hysterectomy for women at population risk for ovarian cancer.Entities:
Keywords: Hysterectomy counseling; Opportunistic salpingectomy
Year: 2021 PMID: 34295957 PMCID: PMC8281582 DOI: 10.1016/j.gore.2021.100824
Source DB: PubMed Journal: Gynecol Oncol Rep ISSN: 2352-5789
Demographics.
| Characteristic | n (%) or mean ± standard deviation |
|---|---|
| Age | 49.95 ± 10.8 |
| Years in Practice | 19.2 ± 10.6 |
| 10 years or less | 25 (24.8) |
| 10 + years | 76 (75.2) |
| Gender | |
| Female | 61 (58.1) |
| Male | 44 (41.9) |
| Race | |
| White, non-hispanic | 87 (82.9) |
| Asian or Pacific Islander, non-hispanic | 7 (6.7) |
| Hispanic/Latino | 6 (5.7) |
| Black or African American, non-hispanic | 2 (1.9) |
| Other, non-hispanic (includes Multiracial and AI/AN) | 3 (2.9) |
| Practice Region | |
| Midwest | 28 (26.7) |
| South | 29 (27.6) |
| West | 26 (24.8) |
| Northeast | 22 (21.0) |
| Residency Region | |
| South | 32 (30.8) |
| Northeast | 27 (26.0) |
| Midwest | 30 (28.8) |
| West | 15 (14.4) |
| Primary Medical Specialty | |
| General Obstetrics and Gynecology | 87 (84.5) |
| Gynecology | 10 (9.7) |
| Other (includes MFMs, Urogynecology, etc) | 5 (4.9) |
| Obstetrics | 1 (1.0) |
| Practice Setting | |
| Ob-gyn Partnership/Group | 42 (40.0) |
| Multi-specialty Group | 23 (21.9) |
| University Faculty Practice | 16 (15.2) |
| Hospital, Clinic, or HMO/Staff Model | 16 (15.2) |
| Solo Private Practice | 8 (7.6) |
| Practice Location | |
| Suburban | 28 (26.7) |
| Urban, non-inner city | 31 (29.5) |
| Mid-sized town (10,000–50,000) | 21 (20.0) |
| Urban, inner city | 15 (14.3) |
| Rural | 9 (8.6) |
| Military | 1 (1.0) |
Frequency of the following influencing decision to perform bilateral salpingectomy with ovarian conservation in perimenopausal women aged 45–65 at the time of benign hysterectomy.
| Frequencies | Years in Practice | |||||
|---|---|---|---|---|---|---|
| 0% of the time | ≥75% of the time | 0% of the time | ≥75% of the time | |||
| Factors | 10 years or less | 10 + years | 10 years or less | 10 + years | ||
| Patient's age: 45–50 years | 16 (10.9) | 69 (46.9) | 6 (33.3) | 8 (14.0) | 12 (66.7) | 49 (86.0) |
| Patient’s age: 51–55 years | 19 (12.9) | 60 (40.8) | 6 (37.5) | 11 (20.4) | 10 (62.5) | 43 (79.6) |
| Patient’s age: 56–60 years | 23 (15.6) | 57 (38.8) | 10 (55.6) | 11 (21.2) | 8 (44.4) | 41 (78.8) |
| Patient’s age: 61–65 years | 26 (17.7) | 53 (36.1) | 10 (52.6) | 14 (28.0) | 9 (47.4) | 36 (72.0) |
| Menopausal status | 21 (14.3) | 42 (35.4) | 7 (46.7) | 11 (22.4) | 8 (53.3) | 38 (77.6) |
| Preoperative FSH levels | 64 (43.5) | 8 (11.1) | 18 (1 0 0) | 38 (84.4) | 0 (0) | 7 (15.6) |
| Family history of breast, ovarian or colon cancer | 9 (6.1) | 83 (56.5) | 3 (15.8) | 5 (7.9) | 16 (84.2) | 58 (92.1) |
| Family age of menopause | 52 (35.4) | 11 (7.5) | 13 (92.9) | 31 (75.6) | 1 (7.1) | 10 (24.4) |
| Current menopausal symptomatology | 34 (23.1) | 29 (19.7) | 9 (75.0) | 18 (43.9) | 3 (25.0) | 23 (56.1) |
| History of pelvic inflammatory disease (PID) or tubal disease (n = 136) | 38 (25.9) | 24 (16.3) | 13 (92.0) | 20 (47.6) | 1 (7.1) | 22 (52.4) |
p < .05
Frequency of discussing the following factors when counseling perimenopausal women aged 45–65 undergoing bilateral salpingectomy with ovarian conservation at the time of benign hysterectomy.
| Factors | 0% of the time | ≥75% of the time |
|---|---|---|
| Possible ovarian cancer risk reduction | 0 (0) | 106 (72.1) |
| Surgical menopause | 4 (2.7) | 95 (64.6) |
| Severity of symptoms | 6 (4.1) | 87 (59.2) |
| Effect on cardiovascular health | 8 (5.4) | 79 (53.7) |
| Effect on bone health | 7 (4.8) | 79 (53.7) |
| Effect on cognition | 17 (11.6) | 55 (37.4) |
| Possible need for tubal surgery in the future | 19 (12.9) | 53 (36.1) |
| Possible increased operative time | 29 (19.7) | 42 (28.6) |
| Possible increased bleeding | 30 (20.4) | 35 (23.8) |
| Possible increased surgical cost | 56 (38.1) | 14 (9.5) |